MedWatch

Novo expedites diabetes pill application and receives promising data in final study

Danish drug group Novo Nordisk plans to apply for approval of oral semaglutide already in the first half of 2019 instead of mid-2019. The advance is triggered by the results of the last study with the diabetes pill, which showed a 51 percent reduction in the number of cardiovascular deaths.

Foto: Novo Nordisk/PR

FDA and EMA might receive Novo Nordisk's  application for approval of oral semaglutide a bit earlier than planned.

This is according to Mads Krogsgaard Thomsen, CSO in Novo Nordisk, after the Danish drug group recently announced the results of the tenth and last of its clinical Pioneer trials with oral semaglutide.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier